Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Dr Paul Dargan
Consultant Physician & Clinical Toxicologist Guys & St Thomas Poisons Unit London, UK
Since these initial reports HPF has been attempted in the treatment of a number of other poisonings
- e.g. carbamazepine, theophylline, salicylates, meprobomate, phenytoin, sodium valproate, paraquat, thallium, dichlorvos, digoxin, tricyclic antidepressants etc
Haemoperfusion: Technique
Blood is pumped (150 - 250 mL/min) through a column containing an adsorbent, usually activated charcoal, coated with a biocompatible ultrathin membrane
In vitro data suggests resins may have adsorptive capacity for lipophilic compounds (Rosenbaum J 1971)
But they are less biocompatible cytokine activation & greater hypocalcaemia/thrombocytopenia
(Pond SM 1991, Rosenbaum J 2000, Franssen EJ 1999)
Haemoperfusion: Technique
A standard haemofiltration / haemodialysis pump can be used perfusion column Anticoagulation (heparin or prostacyclin) is required HPF does not correct electrolyte / acid-base
(Milonovich LM 2001)
disturbances or uraemia
Haemoperfusion: Technique
Adsorptive capacity over time:
- deposition of drug, cellular debris & proteins - maximum capacity of each column ~ 4 hours
Inotropes & other IV drugs should be infused distal to the device to minimise HPF removal
Cost:
(Webb D 1993, Ehlers S 1978, Blye E 1984)
4 Protein binding, water solubility & molecular size are not such limiting factors as with haemodialysis:
- Membrane on cHPF columns is ~ 1-5 mm (compared to the 30-50 mm with HDx membranes) and so doesnt present a significant barrier to solute diffusion
(Ludwig S 1987, Chang T 1975, Webb D 1993)
- Strong affinity of many substances for AC can help overcome protein binding (Bressolle F 1994, Blye E 1984)
Complications of Haemoperfusion
1 Common to all extracorporeal techniques:
- Hypotension: particularly during the first 15 mins
- minimised by priming the circuit & gradually blood flow to overcome internal resistance (~ 25 mmHg)
- Nosocomial infection
Complications of Haemoperfusion
2 Complications specific to HPF:
i) Leucopenia, hypocalcaemia & cytokine activation:
- significant with earlier devices, clinically insignificant with modern ultrathin coated columns
(Kolthammer J 76, Sangster B 81, Rommes J 83 & 92, Vanholder R 99, Singh S 04 )
Complications of Haemoperfusion
2 Complications specific to HPF:
iii) Thrombocytopenia - Up to 50-75% with uncoated adsorbents - Only 10-25 % with ultrathin coated adsorbents - Greatest with cellulose nitrate, lowest with heparin hydrogel and cellulose acetate membranes
(Hampel C 1978, Rommes J 1992, Chang T 1977, Pond S 1979)
- Clinically significant bleeding is reported but is rare, particularly with newer columns (even in combination with anticoagulation) (Rommes J 1992, Singh S 2004)
Complications of Haemoperfusion
2 Complications specific to HPF:
iii) Thrombocytopenia & prostacyclin - In vitro studies have shown prostacyclin (cf heparin) results in a less marked fall in platelet count
(Woods HF 1980, Rommes J 1983)
- There have been a number of case reports/series describing its successful use clinically
(Rommes JH 1992, Kennedy HJ 1985 Langenecker K 1999)
2.
3.
cHPF should only be considered in a small minority of cases of clinically severe poisoning
Two retrospective series suggest mortality in those treated with HPF, possibly due to selection of more severely poisoned patients
(Bismuth C 1979, Hampel G 1987)
However, a number of other series (with similar selection bias) show similar or improved survival
(e.g. Woo O 1984, Traford J 1977, Shannon M 1993)
59,211 72,877
Low Vd (1.4 L/kg) & endogenous clearance (1.3 mL/kg/min) Binds activated charcoal Protein binding ~ 74% and low water solubility - therefore no significant conventional HDx clearance
(Cutler RE 1987)
- 3 recent reports of high-flux HDx with moderate removal / clearance (53-64 mL/min) of carbamazepine
(Tapolyai M 2002 Kielstein J 2002 Schuerer DJE 2000)
- Ileus limited treatment with WBI / MDAC & so treated with HPF at 77hrs post-ingestion
After 1 hr of cHPF:
- Rousable with no further seizures - carbamazepine concentration 176 - 106 mmol/L - T: during HPF 0.17hr post HPF: 6.2 hrs
Graudins A et al Emerg Med 2002
T (hrs)
Controls
MDAC cHPF
19-32
8.6-9.5 2.6-10.7
59-90
102-113 88-129
(Hundt HK 83, Vreeth 86, Cutler RE 184) (Wason S 92, Boldy D 87, Monty-Cabrera 96) (Chan K 81, Leslie P 83, De Groot G 84, Nilsson 84)
- particularly cases with poor gut motility or those that are deteriorating despite MDAC
Theophylline poisoning is less common than 10 years ago, but still occurs:
- NPIS(L) 2002: 34 cases requiring ICU admission
Theophylline kinetics:
- Low Vd 0.5 L/kg & endogenous clearance (0.7mL/kg/min) - 40 - 50 % protein bound - binds AC - T1/2 19 - 34hrs in overdose
HDx Major toxicity during 39% or after procedure Clearance (mL/min) 185 Complications NIL
HPF 28%
294
1x GI bleed 1x bleed at access site
(Controls: Cutler RE 1987) (MDAC: Radowski 1986, Ohning B 1986, Sessler S 1985) (HDx: Lee C 1979, Hootkins R 1980, Shannon M 1993 & 1997, Gitomer J 2001) (cHPF: Woo OF 1985, Heath A 1987, Hootkins R 1980, Shannon M 1993 & 1997)
cHPF is generally the treatment of choice in severe theophylline poisoning if an extracorporeal treatment is required
?? Prophylactically in a symptomatic patient with serum theophylline: - acute poisoning: > 100 mg/L (600 mmol/L) - chronic poisoning: > 60 mg/L (330 mmol/L), particularly in patients > 60yrs of age
(Olson KR 85, Sessler CN 90, Shannon MW 87, 93 & 99)
?? Lower threshold: - in patients with severe co-morbidity - if intractable vomiting and/or ileus prevent MDAC administration ( Shannon MW 93 & 99)
However, they have effective alternative treatments &/or Vd & so cHPF has no impact on overall body burden and is not indicated
(Pond S 1979 & 1991, Blye E 1984 , Winchester J 2002)
Salicylates:
- cHPF and HDx increase total body clearance ~ 2x - HDx is the extracoporeal treatment of choice in severe poisoning as it also corrects acid-base and electrolyte disturbances (Pond SM 1984, Jacobsen D 1984)
(Scorgie KA 2001)
SCN spherical polymer carbon
CONCLUSIONS
Extracorporeal techniques such as cHPF are indicated in only a limited number of severe cases of poisoning with selected agents Modern coated charcoal HPF columns are associated with many fewer adverse effects
There have been no controlled studies assessing the impact of cHPF on outcome and no studies which allow a direct comparison between cHPF and either HDx or MDAC
CONCLUSIONS
The limited data available suggests that:
- there is a continuing role for cHPF in severe theophylline & carbamazepine poisoning
- particularly in patients who are deteriorating despite MDAC or in those in whom MDAC use is limited by ileus Future developments in carbon technologies may allow an expansion in the indications for cHPF in toxicology & increased efficacy
Charcoal Haemoperfusion: Does it still have a role in the management of the poisoned patient ?
Yes, probably, in severe theophylline and carbamazepine poisoning
But the level of evidence is poor